Please use this identifier to cite or link to this item:
|Title:||Voyage au bout de la nuit: Aβ and tau imaging in dementias.|
|Authors:||Zwan, M D;Okamura, N;Fodero-Tavoletti, Michelle T;Furumoto, S;Masters, Colin L;Rowe, Christopher C;Villemagne, Victor L|
|Affiliation:||Department of Nuclear Medicine and Centre for PET Austin Health, Heidelberg, Victoria, Australia -|
|Citation:||The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (aimn) [and] the International Association of Radiopharmacology (iar), [and] Section of the Society of Radiopharmaceutica 2014; 58(4): 398-412|
|Abstract:||The last decade has witnessed the development and characterization of tracers for the evaluation of neuropathology in vivo. The introduction of these tracers, namely β-amyloid (Aβ) and later tau, are providing the tools to change the landscape and refine our understanding of Aβ and tau deposition in the brain, allowing to investigate the causes, refine diagnosis and improve treatment of major neurodegenerative conditions such as Alzheimer's disease (AD), chronic traumatic encephalopathy (CTE) and frontotemporal lobar degeneration (FTLD). Aβ and tau imaging allow examination of the regional and global changes of these disease markers over time as well as their relationship with other relevant parameters such as cognitive performance and neurodegenerative changes. Aβ and tau imaging will enable to establish the role Aβ and tau play -and interplay- in aging and disease. Aβ and tau imaging value resides in being not only diagnostic, prognostic or progression markers, but also surrogate markers of disease, crucial for patient recruitment and efficacy evaluation of disease-specific therapies.|
|Internal ID Number:||25358680|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.